Clinical time course of COVID-19, its neurological manifestation and some thoughts on its management
Yifan Zhoua, Wei Lib, David Wangc, Ling Maoa, Huijuan Jina, Yanan Lia, Candong Honga, Shengcai Chena, Jiang Changd, Quanwei Hea, Mengdie Wanga, Bo Hua✉
- aDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
- bDepartment of Neurology, Army Medical Center of PLA, Chongqing 400042, China
- cNeurovascular Division, Barrow Neurological Institute, Saint Joseph Hospital Medical Center, Phoenix, Arizona 85013, USA
- dDepartment of Epidemiology and Biostatistics, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Sciences and Technology, Wuhan 430030, China
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Coronavirus disease-2019 (COVID-19) has become a global pandemic. COVID-19 runs its course in two phases, the initial incubation phase and later clinical symptomatic phase. Patients in the initial incubation phase often have insidious clinical symptoms, but they are still highly contagious. At the later clinical symptomatic phase, the immune system is fully activated and the disease may enter the severe infection stage in this phase. Although many patients are known for their respiratory symptoms, they had neurological symptoms in their first 1-2 days of clinical symptomatic phase, and ischaemic stroke occurred 2 weeks after the onset of the clinical symptomatic phase. The key is to prevent a patient from progressing to this severe infection from mild infection. We are sharing our experience on prevention and management of COVID-19.